My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TriSalus Life Sciences, Inc. - Common Stock (NQ:TLSI)

4.250 -0.070 (-1.62%)
Streaming Delayed Price Updated: 9:32 AM EDT, Oct 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,600
Open 4.230
Bid (Size) 4.250 (1)
Ask (Size) 4.390 (4)
Prev. Close 4.320
Today's Range 4.230 - 4.330
52wk Range 3.420 - 5.880
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
TriSalus Life Sciences to Participate in Upcoming September Investor Conferences
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Inc (NASDAQ:TLSI) Reports Strong Q2 2025 Revenue Growth and Narrowed Losses
TriSalus Life Sciences reports strong Q2 2025 revenue growth of 52% YoY to $11.2M, beating estimates. Losses narrow as commercialization of TriNav and PEDD platform gains momentum. 
Via Chartmill

Performance

YTD
-14.7%
-14.7%
1 Month
-4.1%
-4.1%
3 Month
-14.7%
-14.7%
6 Month
-23.4%
-23.4%
1 Year
-2.1%
-2.1%

More News

Read More
TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 Guidance
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique
From TriSalus Life Sciences
Via Business Wire
Examining the Future: TriSalus Life Sciences's Earnings Outlook
Via Benzinga
Earnings Scheduled For August 12, 2025
Via Benzinga
TriSalus Life Sciences to Participate in the Canaccord Genuity 45th Annual Growth Conference
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences to Host Second Quarter 2025 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results
From TriSalus Life Sciences
Via Business Wire
Earnings Scheduled For May 15, 2025
Via Benzinga
TriSalus Life Sciences’ Q4 Loss Exceeds Projections, Revenue Tops Estimates – Retail Stays Pessimistic
Via Stocktwits
TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav® Infusion System Mapping
From TriSalus Life Sciences
Via Business Wire
Earnings Scheduled For March 27, 2025
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
TriSalus Life Sciences® Announces That Its Researchers Received Two JVIR Top Paper Awards for the Publication of “Intra-arterial Pressure-Enabled Drug Delivery™ Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model”
From TriSalus Life Sciences
Via Business Wire
3 Stocks With Robust Growth Outlooks Insiders Are Buying
Via MarketBeat
TriSalus Life Sciences Announces Key Appointments to Board of Directors
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed
From TriSalus Life Sciences
Via Business Wire

Frequently Asked Questions

Is TriSalus Life Sciences, Inc. - Common Stock publicly traded?
Yes, TriSalus Life Sciences, Inc. - Common Stock is publicly traded.
What exchange does TriSalus Life Sciences, Inc. - Common Stock trade on?
TriSalus Life Sciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for TriSalus Life Sciences, Inc. - Common Stock?
The ticker symbol for TriSalus Life Sciences, Inc. - Common Stock is TLSI on the Nasdaq Stock Market
What is the current price of TriSalus Life Sciences, Inc. - Common Stock?
The current price of TriSalus Life Sciences, Inc. - Common Stock is 4.250
When was TriSalus Life Sciences, Inc. - Common Stock last traded?
The last trade of TriSalus Life Sciences, Inc. - Common Stock was at 10/13/25 09:32 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.